GlassScriptPhysician profile
Laurel A Feiner
NPI 1972556454
$1,129.41
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $278 · 2021: $265.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $426.12 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $97.53 | 2019-2020 | |
| Lilly USA, LLC | $94.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $82.73 | 2019 | |
| Allergan, INC. | $72.02 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $69.89 | 2019 | |
| Horizon Therapeutics Plc | $66.06 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.81 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $53.53 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $25.92 | 2020 | |
| Alexion Pharmaceuticals, INC. | $25.70 | 2019-2020 | |
| Biotissue Holdings INC. | $19.02 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.98 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.44 | 2019 | |
| Omeros Corporation | $12.88 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Feiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.